The growing numbers of individuals with mental health disorders, notably in the schizophrenia and bipolar disorder demographics, highlight the promising market prospects for IGALMI. Its distinct sublingual formulation provides a quick onset of effects, making it a potentially valuable choice in addressing these conditions.